Ozempic got 70x Cheaper in India - The Real Investment Opportunity

A drug that cost ₹90,000 per month globally is now available in India for just ₹1,290. That’s a 50–70x price drop. And this isn’t just a pharma story. This is one of the biggest market shifts happening right now affecting: Healthcare access Consumer behavior Food & fitness trends And multiple industries beyond pharma After the patent expiry on March 20, 2026, semaglutide (the molecule behind Ozempic) entered India- triggering intense competition among Indian pharma companies. Prices didn’t just fall. They collapsed. But here’s the real insight: The biggest opportunity may not lie in pharma companies at all. It lies in the ecosystem around it. In this video, we break down: What Ozempic / GLP-1 actually does (in simple terms) Why prices crashed so sharply in India What’s happening globally (US trends & real data) And most importantly — where investors should actually look From diagnostics to medical devices to consumption patterns — this is a classic case of proxy investing. Because the smartest investors don’t chase the obvious. They understand what changes underneath the surface. If you want to understand one of the biggest emerging investment themes in India - this is worth your time. ⚠️ Disclaimer: This video is for educational purposes only and not investment advice. Please do your own research before making any investment decisions.